BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/23/2024 9:40:30 AM | Browse: 114 | Download: 173
 |
Received |
|
2023-12-28 23:34 |
|
Peer-Review Started |
|
2023-12-28 23:34 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-02-19 20:07 |
|
Revised |
|
2024-03-13 16:03 |
|
Second Decision |
|
2024-04-22 02:55 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-04-22 06:10 |
|
Articles in Press |
|
2024-04-22 06:10 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-15 08:22 |
|
Publish the Manuscript Online |
|
2024-05-23 09:40 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Neoadjuvant treatment of pancreatic ductal adenocarcinoma: Whom, when and how
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Nebojsa Manojlovic, Goran Savic and Stevan Manojlovic |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nebojsa Manojlovic, PhD, Associate Professor, Clinic for Gastroenterology and Hepatology, Military Medical Academy, Faculty of Medicine of the Military Medical Academy, University of Defence, Crnotravska 17, Belgrade 11000, Serbia. nebojsa.manojlovic1@gmail.com |
| Key Words |
Pancreatic adenocarcinoma; Neoadjuvant treatment; Chemotherapy; Upfront surgery; Radiotherapy; Response evaluation |
| Core Tip |
Pancreatic ductal adenocarcinoma, which is notorious for its aggressiveness and poor prognosis, remains an area of great unmet medical need. The most important determinant of survival is surgical resection. Nearly 60% of patients who undergo upfront surgery for resectable tumours are unable to receive adequate adjuvant chemotherapy (CHT). An important paradigm shift to achieve better outcomes has been the sequence of therapy, with neoadjuvant CHT preceding surgery. Three surgical stages have emerged for the preoperative assessment of nonmetastatic pancreatic cancers: Resectable, borderline-resectable and unresectable locally advanced tumours. In the development of new neoadjuvant and induction strategies, the distinct molecular and biological characteristics of the various pancreatic cancer subgroups need to be integrated to optimize the selection and sequencing of both established and novel treatment modalities that may improve survival outcomes. |
| Publish Date |
2024-05-23 09:40 |
| Citation |
<p>Manojlovic N, Savic G, Manojlovic S. Neoadjuvant treatment of pancreatic ductal adenocarcinoma: Whom, when and how. <i>World J Gastrointest Surg</i> 2024; 16(5): 1223-1230</p> |
| URL |
https://www.wjgnet.com/1948-9366/full/v16/i5/1223.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v16.i5.1223 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
